| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Medical and professional news |
| Population | Men |
| Source | Doximity Op-Med |
| URL | opmed.doximity.com/articles/testosterone-levels-increase-after-treatment-with-glp-1-receptor-agonists (opens in a new tab) |
Specific Claim Evaluated
In a retrospective analysis of 1,629 obese men treated with semaglutide or tirzepatide, median total testosterone rose from 320 to 419 ng/dL; causality cannot be established.
Primary Research Supporting or Contradicting the Claim
A meta-analysis found that GLP-1 receptor agonists increased total testosterone in overweight and obese men, with the change correlated with weight loss, and could not demonstrate a direct testicular action (Salvio et al., 2025).
Corrected Evidence-Based Interpretation
The report is correct.
Rationale for Grade
The article reports the retrospective design, nonstandardized timing of testosterone measurement and possible residual confounding, and presents GLP-1 receptor agonists as an adjunct rather than a replacement for standard treatment.
References
- Salvio G, Ciarloni A, Ambo N, Bordoni M, Perrone M, Rossi S, Balercia G. Effects of glucagon-like peptide 1 receptor agonists on testicular dysfunction: a systematic review and meta-analysis. Andrology. 2025;13(8):2022-2034. PMID
Supporting excerpt: "The limitations of the current literature do not allow to demonstrate a direct action"